Zostavax Mechanism of Action

vaccine, varicella-zoster




Zuellig Pharma
Full Prescribing Info
Therapeutic Class: ZOSTAVAX is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella-zoster virus (VZV).
Pharmacology: Special Population: Immunogenicity in subjects with HIV infection: In a double-blind, placebo-controlled randomized clinical trial, ZOSTAVAX was administered as a two-dose regimen to human immunodeficiency virus (HIV)-infected adults (18 years of age or older) on potent combination antiretroviral therapy with conserved immune function (CD4+ T cell count ≥200 cells/µL). Although a two-dose regimen was used in this study, ZOSTAVAX is administered as a single dose regimen (see Dosage & Administration). In this study, a total of 295 subjects received dose 1 and 286 subjects received dose 2. Compared with placebo, ZOSTAVAX induced a higher VZV-specific gpELISA antibody GMT at Week 6 (6 weeks following dose 1) and Week 12 (6 weeks following dose 2) (GMT of 534.4 and 530.3 vs. 263.7 and 250.3 gpELISA units/ml, respectively). The geometric mean fold-rises of the VZV antibody response, as measured by gpELISA, from baseline to Week 6 and Week 12 were 1.78 (95% CI: [1.64 to 1.92]) and 1.80 (95% CI: [1.66 to 1.95]), respectively, in vaccine recipients and 1.05 (95% CI: [0.98 to 1.12]) and 1.04 (95% CI: [0.96 to 1.13]), respectively, in placebo recipients. (See Contraindications.)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in